Date: 21st of October 2020 from 2pm to 5pm
Language: English
Groups: 1
PAX: 40 (max. group size 40 people)


Who we are
Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO), focused exclusively on client projects. From its headquarters in Laupheim, Germany, and Milford, MA, Rentschler Biopharma offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support.
This first U.S. site, conveniently located in the Boston Biotech-hub, was acquired in early 2019. The FDA, EMA and Health Canada licensed, 93,000 square foot facility will be qualified as a multi-product site offering clients innovative solutions. The first step in establishing Rentschler Biopharma’s center of excellence in North America is a 500 L single-use bioreactor that will be operational by mid-2020. The next steps include another building for large-scale SU manufacturing and lab capacity for new therapeutic modalities. The company plans to leverage its expertise for client projects through every phase, be it early stage development or clinical and commercial production. With its innovative and highly flexible business model, the Milford site is already taking on new projects, including complex and difficult-to-manufacture proteins, such as multispecific antibodies. In total, Rentschler Biopharma expects to invest around $55 million in these expansions and to hire at least 75 additional people at the site to keep pace with the site development and business growth.
Rentschler Biopharma is a family-owned company with more than 1.000 employees. For further information, please visit

What to expect
The visit will entail presentations, a guided VIP site tour and will provide room for questions and networking. Refreshments will be served. A detailed agenda announcing presentation titles and speakers will follow.


Book Online at (password required)
By Phone you can call us on +44 (0) 207 952 6112
Email your interest to